Recent Updates
Recently added Catalysts
BHVN Negative Sentiment Score: 30/100

FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia

Wednesday, November 5, 2025 1 min read
Key Takeaway: Biohaven Ltd. has received a Complete Response Letter from the FDA regarding its New Drug Application for VYGLXIA (troriluzole), intended for the treatment of spinocerebellar ataxia. This indicates that the FDA has not approved the drug at this time, which could impact the availability of treatment for patients suffering from this condition. The company will need to address the FDA's concerns before resubmitting the application.

Market Sentiment Analysis

CONCERNS & RISKS

  • FDA issued a Complete Response Letter for VYGLXIA.
  • The application for VYGLXIA was not approved.
  • This setback may delay treatment options for patients with SCA.

Full Press Release Details

NEW HAVEN, Conn.,Nov. 4, 2025/PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) seeking approval of VYGLXIA (troriluzole) for the treatment of spinocerebellar ataxia (SCA).

Frequently Asked Questions

What is VYGLXIA used for?

VYGLXIA (troriluzole) is intended for the treatment of spinocerebellar ataxia.

What did the FDA issue for VYGLXIA?

The FDA issued a Complete Response Letter regarding the New Drug Application for VYGLXIA.

What does a Complete Response Letter mean?

A Complete Response Letter indicates that the FDA has not approved the drug application.

How does this affect Biohaven?

This setback may delay the availability of VYGLXIA for patients with spinocerebellar ataxia.

Tags: BHVN Viatris Investor Conferences Healthcare Biohaven VYGLXIA troriluzole FDA spinocerebellar ataxia
Last updated: Nov 5, 2025